Deprescribing in psychiatry: challenges and opportunities
https://doi.org/10.21886/2219-8075-2020-11-3-6-14
Abstract
Many recommendations, protocols describe the indications for starting medication, but only some of them indicate when they should be discontinued. An analysis of publications indicates a deficit of research in this area, especially in psychiatry. As part of this review, we tried to provide information that provides valuable information about this procedure, about the experience of other countries. Based on a literature review, it was found that in some countries there is already consensus on how to identify a patient who may be reevaluated, recommendations and algorithms have been developed for this procedure with minimal risk to the patient.
About the Authors
Zh. B. Bibekova
Karaganda Medical University
Kazakhstan
Kazakhstan
Zhazira B. Bibekova — assistant of Neurology, neurosurgery, psychiatry and rehabilitology department
Karaganda
Kirill Vladimirovich Zarovnyy
Karaganda Medical University
Kazakhstan
Kazakhstan
Kirill V. Zarovnyy — resident doctor of Neurology, neurosurgery, psychiatry and rehabilitology department
Karaganda
V. O. Tsyganova
Kazakh-Russian Medical University
Kazakhstan
Kazakhstan
Viktoriya O. Tsyganova — resident doctor of psychiatry, narcology and neurology department
Almaty
References
1. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS One. 2016;11(4). https://doi.org/10.1371/journal.pone.0151066
2. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust 2014; 201:386–9. https://doi.org/10.5694/mja13.00200
3. Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS One. 2016;11(8). https://doi.org/10.1371/journal.pone.0161248
4. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J. 2015. March;45(3):352–6. https://doi.org/10.1111/imj.12693
5. Betteridge TM, Frampton CM, Jardine DL. Polypharmacy—we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J 2012. February;42(2):208–11. https://doi.org/10.1111/j.1445-5994.2011.02690.x
6. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One. 2015;10(4). https://doi.org/10.1371/journal.pone.0122246
7. Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. International journal of clinical pharmacy 2014;36(1):26–9. https://doi.org/10.1007/s11096-013-9871-z
8. Grudnikoff, Eugene MD; Bellonci, Christopher MD. Deprescribing in Child and Adolescent Psychiatry—A Sorely Needed Intervention. American Journal of Therapeutics. 2017. 24(1):e1-e2. https://doi.org/10.1097/MJT.0000000000000552.
9. Gupta, S., Cahill, J., & Miller, R. (2018). Deprescribing antipsychotics: A guide for clinicians. BJPsych Advances, 24(5), 295-302. https://doi.org/10.1192/bja.2018.2
10. Woodward M.C. Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications. J. Pharm. Pract. Res. 2003;33:323–328. https://doi.org/10.1002/jppr2003334323.
11. Sinnott C, Hugh SM, Boyce MB, Bradley CP. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. Br J Gen Pract 2015. March;65(632):e184–91. https://doi.org/10.3399/bjgp15X684001
12. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 2012;13:56 https://doi.org/10.1186/1471-2296-13-56
13. Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. Health Aff (Millwood) 2011;30(12):2437–48. https://doi.org/10.1377/hlthaff.2011.0923
14. Gupta, Swapnil & Cahill, John. A Prescription for "Deprescribing" in Psychiatry. Psychiatric services (Washington, D.C.). 2016. 67(8). https://doi.org/10.1176/appi.ps.201500359.
15. Essock SM, Covell NH, Leckman-Westin E, et al: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services/ 2009; 60(12): 1595–1602 https://doi.org/10.1176/ps.2009.60.12.1595
16. Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Journal of Clinical Psychiatry. 2004;65(10):1377–1388 https://doi.org/10.4088/jcp.v65n1013
17. Stahl SM, Grady MM: A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry. 2004;11(3):313–327. https://doi.org/10.2174/0929867043456070
18. Gupta, Swapnil & Miller, Rebecca. Deprescribing and Its Application to Psychiatry: Controversies and Clinical Implications. January 2019. 137-153. https://doi.org/10.1007/978-3-030-02732-2_6.
19. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738–47. https://doi.org/10.1111/bcp.12386
20. Swofford, CD, Kasckow, JW, Scheller-Gilkey, G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research. 1996;20(1-2): 145–51 https://doi.org/10.1016/0920-9964(95)00068-2
21. Deegan, PE, Drake, RE Shared decision making and medication management in the recovery process. Psychiatric Services, 2006;57(11): 1636–9. https://doi.org/10.1176/ps.2006.57.11.1636
22. Stanhope, V, Ingoglia, C, Schmelter, B, et al. Impact of person-centered planning and collaborative documentation on treatment adherence. Psychiatric Services, 2013; 64(1): 76–9. https://doi.org/10.1176/appi.ps.201100489.
23. Jacobson, L, Greeley, D. What is recovery? A conceptual model and explication. Psychiatric Services. 2001;52(4): 482–5. https://doi.org/10.1176/appi.ps.52.4.482
24. Taylor DJ, Pruiksma KE. Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review. Int Rev Psychiatry. 2014;26(2):205–13. https://doi.org/10.3109/09540261.2014.902808
25. Velkoff V. The next four decades: The older population in the United States: 2010-2050. Current Population Reports 2010:1-14. http://books.google.com/books?id=gALA2NWAFZ4C.
26. Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015; 11(3):332-84. https://doi.org/10.1016/j.jalz.2015.02.003
27. Renn BN, Asghar-Ali AA, Thielke S, et al. A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia. Am J Geriatr Psychiatry. 2018;26(2):134–147. https://doi.org/10.1016/j.jagp.2017.09.027
28. Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 (9). https://doi.org/10.1002/14651858.CD001191.pub4.
29. Mitchell SL, Morris JN, Park PS, Fries BE. Terminal care for persons with advanced dementia in the nursing home and home care settings. J Palliat Med. 2004 Dec; 7(6):808-16. https://doi.org/10.1089/jpm.2004.7.808
30. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010 Jun 1; 27(6):435-49. https://doi.org/10.2165/11536760-000000000-00000
31. Vetrano DL, Tosato M, et al. Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study. Alzheimers Dement. 2013 Sep; 9(5):587-93. https://doi.org/10.1016/j.jalz.2012.09.009.
32. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1):CD005593. https://doi.org/10.1002/14651858.CD005593
33. Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. Int J Neuropsychopharmacol. 2020;23(2):125–131. https://doi.org/10.1093/ijnp/pyz068
34. Brett J, Daniels B, Karanges EA, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol. 2017;83(11):2581–2588. https://doi.org/10.1111/bcp.13369
35. Arah OA, Westert GP, Hurst J, Klazinga NS. A conceptual framework for the OECD Health Care Quality Indicators Project. Int J Qual Health Care. 2006 (1):5-13. https://doi.org/10.1093/intqhc/mzl024
36. Carinci F, Van Gool K, Mainz J, et al. Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. Int J Qual Health Care. 2015. 27(2):137–146. https://doi.org/10.1093/intqhc/mzv004
37. Yang SY, Chen LY, Najoan E, et al. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry Clin Neurosci. 2018 Aug; 72(8):572-579. https://doi.org/10.1111/pcn.12676
38. Toto S, Grohmann R, Bleich S, et al. Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. Int J Neuropsychopharmacol. 2019 Sep 1; 22(9):560-573. https://doi.org/10.1093/ijnp/pyz037
39. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry. 1981. 138(9):1243–1244. https://doi.org/10.1176/ajp.138.9.1243
40. Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf. 2008. 31(7):597–607. https://doi.org/10.2165/00002018-200831070-00005
41. Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. Int J Neuropsychopharmacol. 2020;23(2):125–131. https://doi.org/10.1093/ijnp/pyz068
42. Bjerre LM, Farrell B, Hogel M, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27. PMID: 29358245
43. Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174‐179. https://doi.org/10.5694/mja2.50015
44. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339–351. PMID: 29760253
45. Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians' Views on Deprescribing in Everyday Practice. Ann Fam Med. 2017;15(4):341–346. https://doi.org/10.1370/afm.2094
46. Kouladjian L, Gnjidic D, Reeve E, Chen TF, Hilmer SN. Health Care Practitioners' Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. Ann Pharmacother. 2016;50(8):625‐636. https://doi.org/10.1177/1060028016652997
47. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS One. 2016;11(4):e0151066. https://doi.org/10.1371/journal.pone.0151066
48. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLoS One. 2015;10(4):e0122246. Published 2015 Apr 7. https://doi.org/10.1371/journal.pone.0122246
49. Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015;351:h4326. Published 2015 Sep 1. https://doi.org/10.1136/bmj.h4326
50. Glover, G.; Williams, R.; et al. Prescribing of Psychotropic Drugs to People with Learning Disabilities and/or Autism by General Practitioners in England; Public Health England: London, UK, 2015. 67 p.
51. Flood B. De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary. Pharmacy (Basel). 2018;6(2):28. Published 2018 Mar 30. https://doi.org/10.3390/pharmacy6020028.
52. British Pharmacological Society. Ten Principles of Good Prescribing; British Pharmacological Society: London, UK, 2012.
Review
For citations:
Bibekova Zh.B., Zarovnyy K.V., Tsyganova V.O. Deprescribing in psychiatry: challenges and opportunities. Medical Herald of the South of Russia. 2020;11(3):6-14. https://doi.org/10.21886/2219-8075-2020-11-3-6-14
Views:
772
Email this article 